# Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

> **NCT03882801** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Obstructive Sleep Apnea (OSA)

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03882801
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-10
- **Primary completion:** 2019-10-22
- **Final completion:** 2019-10-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882801, "Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03882801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*